Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers

Journal of the American College of Cardiology

Volumn 68, Issue 21, 2016, Pages 2299-2307

  Kumar, Saurabh ^a   Baldinger, Samuel H ^b   Gandjbakhch, Estelle ^c   Maury, Philippe ^d   Sellal, Jean Marc ^e,f,g,h   Androulakis, Alexander F A ⁱ   Waintraub, Xavier ^c   Charron, Philippe ^c,j,k   Rollin, Anne ^d   Richard, Pascale ^l   Stevenson, William G ^a   Macintyre, Ciorsti J ^a   Ho, Carolyn Y ^a   Thompson, Tina ^m   Vohra, Jitendra K ^m   Kalman, Jonathan M ^m   Zeppenfeld, Katja ⁱ   Sacher, Frederic ^e,f,g   Tedrow, Usha B ^a   Lakdawala, Neal K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f L'Institut de Rythmologie et Modélisation Cardiaque LIRYC   (France)

^g Serv Hospitalo Universitaire de P   (France)

^h UNIVERSITY HOSPITAL OF NANCY   (France)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ICAN Institute for Cardiometabolism and Nutrition   (France)

^k LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

atrial fibrillation; cardiomyopathy; complete atrioventricular block; genetics; heart failure; ventricular tachycardia

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; GENE; GENE MUTATION; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HETEROZYGOTE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LMNA GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; PHENOTYPE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SUDDEN CARDIAC DEATH; THROMBOEMBOLISM; ARRHYTHMIAS, CARDIAC; CLINICAL TRIAL; FRANCE; GENETICS; HEART LEFT VENTRICLE FUNCTION; INCIDENCE; METABOLISM; MULTICENTER STUDY; MUTATION; NETHERLANDS; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL RATE; TIME FACTOR; TRENDS; VICTORIA; YOUNG ADULT;

LAMIN A;

ADOLESCENT; ADULT; AGED; ARRHYTHMIAS, CARDIAC; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; INCIDENCE; LAMIN TYPE A; MALE; MIDDLE AGED; MUTATION; NETHERLANDS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VICTORIA; YOUNG ADULT;

EID: 84997610257     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.08.058     Document Type: Article

References (24)

1. 1 Pasotti, M., Klersy, C., Pilotto, A., et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 52 (2008), 1250–1260.
2. 2 Lakdawala, N.K., Funke, B.H., Baxter, S., et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail 18 (2012), 296–303.
3. 3 Anselme, F., Moubarak, G., Savoure, A., et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm 10 (2013), 1492–1498.
4. 4 Arbustini, E., Pilotto, A., Repetto, A., et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol 39 (2002), 981–990.
5. 5 Taylor, M.R., Fain, P.R., Sinagra, G., et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol 41 (2003), 771–780.
6. 6 van Rijsingen, I.A., Arbustini, E., Elliott, P.M., et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol 59 (2012), 493–500.
7. 7 Fatkin, D., MacRae, C., Sasaki, T., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341 (1999), 1715–1724.
8. 8 van Tintelen, J.P., Hofstra, R.M., Katerberg, H., et al. High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J 154 (2007), 1130–1139.
9. 9 van Berlo, J.H., de Voogt, W.G., van der Kooi, A.J., et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?. J Mol Med (Berl) 83 (2005), 79–83.
10. 10 Aliot, E.M., Stevenson, W.G., Almendral-Garrote, J.M., et al. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Heart Rhythm 6 (2009), 886–933.
11. 11 Hinkle, L.E. Jr., Thaler, H.T., Clinical classification of cardiac deaths. Circulation 65 (1982), 457–464.
12. 12 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62 (2013), 1495–1539.
13. 13 van Rijsingen, I.A., Bakker, A., Azim, D., et al. Lamin A/C mutation is independently associated with an increased risk of arterial and venous thromboembolic complications. Int J Cardiol 168 (2013), 472–477.
14. 14 van Rijsingen, I.A., Nannenberg, E.A., Arbustini, E., et al. Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur J Heart Fail 15 (2013), 376–384.
15. 15 Sedlacek, K., Ruwald, A.C., Kutyifa, V., et al. The effect of ICD programming on inappropriate and appropriate ICD therapies in ischemic and nonischemic cardiomyopathy: the MADIT-RIT trial. J Cardiovasc Electrophysiol 26 (2015), 424–433.
16. 16 Corrado, D., Calkins, H., Link, M.S., et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 122 (2010), 1144–1152.
17. 17 Maron, B.J., Spirito, P., Shen, W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298 (2007), 405–412.
18. 18 Gracieux, J., Sanders, G.D., Pokorney, S.D., et al. Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. Int J Cardiol 177 (2014), 990–994.
19. 19 Meune, C., Van Berlo, J.H., Anselme, F., et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med 354 (2006), 209–210.
20. 20 van der Kooi, A.J., Bonne, G., Eymard, B., et al. Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. Neurology 59 (2002), 620–623.
21. 21 Becane, H.M., Bonne, G., Varnous, S., et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol 23 (2000), 1661–1666.
22. 22 van Berlo, J.H., Duboc, D., Pinto, Y.M., Often seen but rarely recognised: cardiac complications of lamin A/C mutations. Eur Heart J 25 (2004), 812–814.
23. 23 Olde Nordkamp, L.R., Postema, P.G., Knops, R.E., et al. Implantable cardioverter-defibrillator harm in young patients with inherited arrhythmia syndromes: a systematic review and meta-analysis of inappropriate shocks and complications. Heart Rhythm 13 (2016), 443–454.
24. 24 Wu, W., Muchir, A., Shan, J., et al. Mitogen-activated protein kinase inhibitors improve heart function and prevent fibrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation 123 (2011), 53–61.